
Dimerix Investor Relations Material
Latest events

Investor Presentation
18 Jun, 2025

Company Presentation
1 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Dimerix Limited
Access all reports
Dimerix Limited is an Australian biopharmaceutical company focused on developing new therapies for rare and progressive diseases, particularly kidney and inflammatory diseases. The company’s lead candidate targets chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease, using a proprietary drug discovery and development platform. Dimerix applies receptor-based science to create treatments that address unmet medical needs in complex diseases with few current therapeutic options. The company is involved in clinical trials to advance its drug candidates towards regulatory approval. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.
Key slides for Dimerix Limited


Company Presentation
Dimerix Limited


Investor Presentation
Dimerix Limited
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
DXB
Country
🇦🇺 Australia